nach oben

Investigational New Drugs

Erschienen in:

01.08.2012 | SHORT REPORT

Combination therapy with the albumin-binding prodrug of doxorubicin (INNO-206) and doxorubicin achieves complete remissions and improves tolerability in an ovarian A2780 xenograft model

verfasst von: Felix Kratz, Iduna Fichtner, Ralph Graeser

Erschienen in: Investigational New Drugs | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Excerpt

We recently reported on the in superior in vivo antitumor efficacy of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (INNO-206, formerly DOXO-EMCH), an albumin-binding prodrug of doxorubicin with acid-sensitive properties (see Fig. 1), in three tumor models in this journal, i.e. in three xenograft models (breast carcinoma M3366, ovarian carcinoma A2780, and small cell lung cancer H209) as well as in an orthotopic pancreatic carcinoma model (AsPC-1) [1] Previously, INNO-206 has shown significantly improved activity over doxorubicin in two xenograft breast cancer models and an orthotopic murine renal cell carcinoma model [2] and recently against resistant and non resistant myeloma (see http//:www.cytrx.com). …

Nur mit Berechtigung zugänglich

Graeser R, Esser N, Unger H, Fichtner I, Zhu A et al. INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model. Invest New Drugs 28:14–19

Kratz F, Warnecke A, Scheuermann K, Stockmar C, Schwab J et al (2002) Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives: improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound. J Med Chem 45:5523–5533CrossRefPubMed

Kratz F (2007) DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials. Expert Opin Investig Drugs 16:855–866CrossRefPubMed

Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46:6387–6392PubMed

Kratz F (2008) Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 132:171–183CrossRefPubMed

Tannock IF, Rotin D (1989) Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 49:4373–4384PubMed

Kratz F, Ehling G, Kauffmann HM, Unger C (2007) Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin. Hum Exp Toxicol 26:19–35CrossRefPubMed

Lebrecht D, Geist A, Ketelsen UP, Haberstroh J, Setzer B et al (2007) The 6-maleimidocaproyl hydrazone derivative of doxorubicin (DOXO-EMCH) is superior to free doxorubicin with respect to cardiotoxicity and mitochondrial damage. Int J Cancer 120:927–934CrossRefPubMed

Unger C, Haring B, Medinger M, Drevs J, Steinbild S et al (2007) Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin. Clin Cancer Res 13:4858–4866CrossRefPubMed

10.

Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55CrossRefPubMed

11.

Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L et al (1998) Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 95:4607–4612CrossRefPubMed

12.

Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA et al (1995) Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 55:3752–3756PubMed

13.

Fukumura D, Duda DG, Munn LL, Jain RK (2010) Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation 17:206–225CrossRefPubMed

14.

Fang J, Nakamura H, Maeda H (2010) The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 63:136–151CrossRefPubMed

15.

Desai N, Trieu V, Yao Z, Louie L, Ci S et al (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12:1317–1324CrossRefPubMed

16.

Dennis MS, Jin H, Dugger D, Yang R, McFarland L et al (2007) Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res 67:254–261CrossRefPubMed

17.

Wunder A, Stehle G, Sinn H, Schrenk HH, Hoff-Biederbeck D et al (1997) Enhanced albumin uptake by rat tumors. Int J Oncol 11:497–507PubMed

18.

Trail PA, Willner D, Lasch SJ, Henderson AJ, Greenfield RS et al (1992) Antigen-specific activity of carcinoma-reactive BR64-doxorubicin conjugates evaluated in vitro and in human tumor xenograft models. Cancer Res 52:5693–5700PubMed

19.

Kratz F, Roth T, Fichtner I, Schumacher P, Fiebig HH et al (2000) In vitro and in vivo efficacy of acid-sensitive transferrin and albumin doxorubicin conjugates in a human xenograft panel and in the MDA-MB-435 mamma carcinoma model. J Drug Targeting 8:305–318CrossRef

20.

Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58:621–681CrossRefPubMed

21.

Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70:440–446CrossRefPubMed

Titel: Combination therapy with the albumin-binding prodrug of doxorubicin (INNO-206) and doxorubicin achieves complete remissions and improves tolerability in an ovarian A2780 xenograft model
verfasst von: Felix Kratz
Iduna Fichtner
Ralph Graeser
Publikationsdatum: 01.08.2012
Verlag: Springer US
Erschienen in: Investigational New Drugs / Ausgabe 4/2012
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-011-9686-5

Springer Medizin

Combination therapy with the albumin-binding prodrug of doxorubicin (INNO-206) and doxorubicin achieves complete remissions and improves tolerability in an ovarian A2780 xenograft model

Excerpt

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2012

Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer

Antiangiogenic treatments and mechanisms of action in renal cell carcinoma

Screening of well-established drugs targeting cancer metabolism: reproducibility of the efficacy of a highly effective drug combination in mice.

SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma

First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study

The HIV reverse transcriptase inhibitor tenofovir induces cell cycle arrest in human cancer cells

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie